Consumption of a ketogenic diet in a mouse model of AD (APP/PS1) reduces total amyloid levels (Van der Auwera et al., 2005), administration of ketone precursors protects from development of cognitive impairment and reduces levels of amyloid and tau pathologies in a transgenic AD mouse model (3xTg) (Kashiwaya et al., 2013), and administration of ketones (the byproduct of the ketogenic diet) improves cognitive function in wild-type mice (Murray et al., 2016). The gene discussed is APP; the disease is Alzheimer disease.